Research Use Only · Not for Human Consumption 30% OFF EVERYTHING · limited time · Free Shipping on $250+ · View Lab Reports
Peptide Research Library

NAD+

The redox coenzyme at the centre of metabolism and ageing research
Nicotinamide adenine dinucleotide; β-NAD; β-DPN; Coenzyme I
For research use only Evidence grade B — limited human data, mostly via precursors Longevity / Bioregulators

NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme present in every living cell, where it serves as a central electron carrier in redox reactions and as a substrate for sirtuins, PARPs and CD38.1 Tissue NAD+ levels have been reported to decline with age across multiple species, including humans, which has driven interest in NAD+ as a longevity target.2 An important caveat: most controlled human data come from oral precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) rather than from NAD+ itself, and while these reliably raise blood or muscle NAD+, they have not consistently produced clinically meaningful functional changes.3 NAD+ is a research compound; it is not an approved drug or supplement for any use.

Structure

Sequence & identity

C₂₁H₂₇N₇O₁₄P₂ · 663.4 g/mol

Dinucleotide of nicotinamide mononucleotide and adenosine monophosphate joined by a pyrophosphate bridge; identity per PubChem CID 5892 (InChIKey BAWFJGJZGIEFAR-NNYOXOHSSA-N).1

What the research shows

Mechanisms studied

NAD+ cycles between its oxidised (NAD+) and reduced (NADH) forms to shuttle electrons through glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation, making it indispensable for ATP generation.1 Beyond redox chemistry, NAD+ is consumed as a co-substrate by sirtuin deacylases, poly(ADP-ribose) polymerases (PARPs) and the cyclic-ADP-ribose synthase CD38, linking cellular NAD+ availability to gene regulation, DNA-damage responses and signalling.1 Because these consuming enzymes and synthetic flux differ by tissue, researchers describe NAD+ homeostasis as a balance between synthesis and degradation that shifts with age and metabolic state.2

Reported in studies

Dosing in the research literature

The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.

Source / modelRegimen reportedNotes
Igarashi et al., NPJ Aging 2022 (NMN precursor)250 mg oral NMN per day for 12 weeks in healthy older menReported as well tolerated; elevated blood NMN and NAD+ versus placebo, with nominally significant gains in gait speed (P=0.033) and left grip strength (P=0.019). Not a study of NAD+ itself.4
Elhassan et al., Cell Reports 2019 (NR precursor)1 g oral NR per day for 21 days, randomised double-blind crossover, 12 men aged 70–80Augmented the skeletal-muscle NAD+ metabolome and lowered circulating IL-6, IL-5, IL-2 and TNF-α; mitochondrial bioenergetics were unchanged.5
Yoshino M. et al., Science 2021 (NMN precursor)250 mg oral NMN per day for 10 weeks in prediabetic postmenopausal womenIncreased insulin-stimulated muscle glucose disposal and muscle insulin signalling; no change in hepatic insulin response or fasting glucose.6
Research use only. Peptigo products are sold to qualified researchers for laboratory use. This information summarises published research for reference and is not medical advice, a dosing recommendation, or directions for human or animal use.
Reported in studies

Effects observed in research

In controlled human trials of NAD+ precursors, supplementation consistently raised measured NAD+ levels in blood or skeletal muscle.45 Reported downstream observations have been more variable: researchers noted modest gains in some muscle-performance measures and improved muscle insulin sensitivity in a prediabetic cohort, alongside reduced inflammatory cytokines in aged muscle.456 Several investigators caution that raising NAD+ has not yet been shown to translate into consistent, clinically meaningful functional benefit, and that larger standardised trials are needed.3

Honest assessment

Strength of evidence

Grade B

Grade B. The biochemistry of NAD+ as a redox coenzyme is firmly established.1 Human outcome evidence, however, derives mainly from small, short randomised trials of the precursors NMN and NR rather than from NAD+ itself; these show reliable NAD+ elevation but inconsistent functional endpoints.3456 Direct oral bioavailability of intact NAD+ in humans has limited published characterisation. Findings should be read as preliminary.

Handling

Reconstitution & storage

Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.

References

References

  1. PubChem Compound Summary for CID 5892, NAD (nicotinamide adenine dinucleotide). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/5892 (accessed 2026-06-03).
  2. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
  3. Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metabolism. 2015;22(1):31-53. PMID 26118927.
  4. Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5.
  5. Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717-1728.
  6. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. DOI 10.1126/science.abe9985.